Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells

[1]  Karen Blyth,et al.  Serine starvation induces stress and p53 dependent metabolic remodeling in cancer cells , 2012, Nature.

[2]  Oliver Fiehn,et al.  Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue – a GC-TOFMS based metabolomics study , 2012, BMC Genomics.

[3]  G. Hwang,et al.  Potential metabolomic biomarkers for evaluation of adriamycin efficacy using a urinary 1H‐NMR spectroscopy , 2012, Journal of applied toxicology : JAT.

[4]  V. Mootha,et al.  Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation , 2012, Science.

[5]  Masaru Tomita,et al.  Systems Biology, Metabolomics, and Cancer Metabolism , 2012, Science.

[6]  Scarlet F. Brockmöller,et al.  Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery , 2012, Genome Medicine.

[7]  Guangji Wang,et al.  Cellular pharmacokinetic mechanisms of adriamycin resistance and its modulation by 20(S)‐ginsenoside Rh2 in MCF‐7/Adr cells , 2012, British journal of pharmacology.

[8]  K. Kang,et al.  Sulfur amino acid metabolism in doxorubicin-resistant breast cancer cells. , 2011, Toxicology and applied pharmacology.

[9]  Guangji Wang,et al.  Gas chromatography time-of-flight mass spectrometry based metabolomic approach to evaluating toxicity of triptolide , 2011, Metabolomics.

[10]  J. Duan,et al.  GC–TOFMS analysis of metabolites in adherent MDCK cells and a novel strategy for identifying intracellular metabolic markers for use as cell amount indicators in data normalization , 2011, Analytical and bioanalytical chemistry.

[11]  U. Gündüz,et al.  Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. , 2011, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[12]  Guangji Wang,et al.  20(S)-Ginsenoside Rh2 Noncompetitively Inhibits P-Glycoprotein In Vitro and In Vivo: A Case for Herb-Drug Interactions , 2010, Drug Metabolism and Disposition.

[13]  Guangji Wang,et al.  Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib Treatment Show Different Metabolic Responses , 2010, PloS one.

[14]  J. Klawitter,et al.  Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells , 2009, British journal of pharmacology.

[15]  J. Jassem,et al.  Doxorubicin and Paclitaxel versus Fluorouracil, Doxorubicin and Cyclophosphamide as First-Line Therapy for Women with Advanced Breast Cancer: Long-Term Analysis of the Previously Published Trial , 2009, Oncology Research and Treatment.

[16]  David S. Wishart,et al.  MetaboAnalyst: a web server for metabolomic data analysis and interpretation , 2009, Nucleic Acids Res..

[17]  Eun-Young Kim,et al.  A Metabonomic Study on the Biochemical Effects of Doxorubicin in Rats Using 1H-NMR Spectroscopy , 2009, Journal of toxicology and environmental health. Part A.

[18]  Pietro Luigi Indovina,et al.  Metabolomics Using 1H-NMR of Apoptosis and Necrosis in HL60 Leukemia Cells: Differences between the Two Types of Cell Death and Independence from the Stimulus of Apoptosis Used , 2008, Radiation research.

[19]  Stefan Laufer,et al.  Metabolic signature of breast cancer cell line MCF-7: profiling of modified nucleosides via LC-IT MS coupling , 2007, BMC Biochemistry.

[20]  H. Keun,et al.  Application of metabonomics in drug development. , 2007, Pharmacogenomics.

[21]  R. Layfield,et al.  Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. , 2007, International journal of oncology.

[22]  Johan Trygg,et al.  Chemometrics in metabonomics. , 2007, Journal of proteome research.

[23]  L. O’Driscoll,et al.  Biomarkers and multiple drug resistance in breast cancer. , 2006, Current cancer drug targets.

[24]  C. Fenselau,et al.  Alterations in the mitochondrial proteome of adriamycin resistant MCF-7 breast cancer cells. , 2006, Journal of proteome research.

[25]  J. Trygg,et al.  Extraction and GC/MS analysis of the human blood plasma metabolome. , 2005, Analytical chemistry.

[26]  Johan Trygg,et al.  High-throughput data analysis for detecting and identifying differences between samples in GC/MS-based metabolomic analyses. , 2005, Analytical chemistry.

[27]  E. Monti,et al.  Role of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin , 2004, BMC Cancer.

[28]  L. Genestier,et al.  Differential Control of Cell Cycle, Proliferation, and Survival of Primary T Lymphocytes by Purine and Pyrimidine Nucleotides1 , 2003, The Journal of Immunology.

[29]  B. Kamen,et al.  Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs , 2002, Cancer Chemotherapy and Pharmacology.

[30]  A. Anel,et al.  Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells. , 2000, Experimental cell research.

[31]  K. Yoshimoto,et al.  The rate of cell growth is regulated by purine biosynthesis via ATP production and G(1) to S phase transition. , 2000, Journal of biochemistry.

[32]  D. Gewirtz,et al.  A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. , 1999, Biochemical pharmacology.

[33]  J. Cummings,et al.  The molecular pharmacology of doxorubicin in vivo. , 1991, European journal of cancer.

[34]  J. Lankelma,et al.  Glycolysis in P‐glycoprotein‐overexpressing human tumor cell lines Effects of resistance‐modifying agents , 1989, FEBS letters.

[35]  R. Lyon,et al.  Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. , 1988, Cancer research.

[36]  S. Wold.  Cross-Validatory Estimation of the Number of Components in Factor and Principal Components Models , 1978 .

[37]  U. Gündüz,et al.  Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins , 2009, Cancer Chemotherapy and Pharmacology.

[38]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[39]  L. Boros,et al.  Detection of Resistance to Imatinib by Metabolic Profiling , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[40]  H. Choi,et al.  The effect of pyrimidine nucleosides on adenosine-induced apoptosis in HL-60 cells , 1998, Journal of Cancer Research and Clinical Oncology.